CTD Holdings, Inc. (OTCQB: CTDH), a distributor and manufacturer of cyclodextrin
products including the orphan drug designated Trappsol® Cyclo™, today
announced the promotion of Dr. Jeffrey Tate to Chief Executive Officer,
following the retirement of C.E. Rick Strattan. Dr. Tate will hold the titles of
President and CEO of CTD Holdings, Inc.; Mr. Strattan will become Executive
Chairman. Dr. Tate has been President of CTD for 3 years and is a seasoned
executive with more than 30 years of experience in both academic and industrial
biotechnology. Mr. Strattan is the founder of the CTD Holdings Family of
Companies and took the company public in 1994.


"Dr. Tate has proven himself to be the best person for the CEO position as we
continue growing the company," Mr. Strattan said. "I look forward to supporting
his excellent work as we continue to move forward."


Said Dr. Tate: "I sincerely appreciate the opportunity to lead the company as we
move into a growth phase fueled by our Sphingo Biotechnology division and the
Trappsol® Cyclo™ orphan drug opportunity. Rick has created a strong
foundation on which to build."


The Company also announced its intention to file a Drug Master File with the
U.S. FDA in the third quarter of 2014 and to move forward with clinical trials
for its orphan drugs designated Trappsol® Cyclo™ product. Protocol
development for that clinical trial is now in progress.


The Company's orphan drug designated Trappsol® Cyclo™ product has been used
under compassionate use Investigational New Drug protocols to treat Niemann-Pick
Type C disease, a genetic disease that is often fatal in young children.


About the Company:  

The CTD Holdings, Inc. Family of Companies distributes and manufactures the
trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives,
and cyclodextrin complexes for research, nutrition, cosmetic and medical
markets. Sphingo Biotechnology, Inc. is developing Trappsol® Cyclo™, an
orphan drug designated product, for the treatment of Niemann Pick Type C, a
fatal genetic disease in young children. NanoSonic Products, Inc. operates the
world's only cGMP pulse drying facility for the production of ultra-pure
cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin
complexes. CTD, Inc. supplies researchers around the globe from the world's
largest catalog of cyclodextrins. The companies offer a wide variety of
cyclodextrin related manufacturing services to worldwide customers, including
custom formulation, manufacturing, and commercial scale supply of pharmaceutical
grade cyclodextrin complexes. For additional information, visit the Company's
websites: www.ctd-holdings.com and www.cyclodex.com 


Safe Harbor Statement: 

This press release contains "forward-looking statements" about the Company's
current expectations about future results, performance, prospects and
opportunities. Statements that are not historical facts, such as "anticipates,"
"believes" and "expects" or similar expressions, are forward-looking statements.
These statements are subject to a number of risks, uncertainties and other
factors that could cause actual results in future periods to differ materially
from what is expressed in, or implied by, these statements. The factors which
may influence the Company's future performance include the Company's ability to
obtain additional capital to expand operations as planned, success in attracting
additional customers and profitable contracts, and regulatory risks associated
with producing food and pharmaceutical grade products. These and other risk
factors are described from time to time in the Company's filings with the
Securities and Exchange Commission, including, but not limited to, the Company's
reports on Forms 10-K and 10-Q. Unless required by law, the Company assumes no
obligation to update or revise any forward-looking statements as a result of new
information or future events. 



FOR FURTHER INFORMATION PLEASE CONTACT: 

Contact: 
Sitrick And Company
Wendy Tanaka
(415) 369-8447
wtanaka@sitrick.com

Thomas Mulligan
(212) 573-6100, Ext. 395
tmulligan@sitrick.com